BHAT et al., 1993 - Google Patents
The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275BHAT et al., 1993
- Document ID
- 6435080007014287339
- Author
- BHAT S
- METTUS R
- Reddy E
- Ugen K
- Srikanthan V
- Williams W
- WEINER D
- Publication year
- Publication venue
- AIDS research and human retroviruses
External Links
Snippet
Our recent studies have indicated that galactosyl ceramide (GalCer) or sulfatide (sul) may serve as an alternate receptor for human immunodeficiency virus (HIV) in neural cells. In this paper, we describe the mapping of GalCer/sul binding region of HIV env glycoprotein …
- 230000027455 binding 0 title abstract description 86
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BHAT et al. | The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275 | |
| Li et al. | CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1 | |
| Page et al. | Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity | |
| Lee et al. | Functional interaction and partial homology between human immunodeficiency virus and neuroleukin | |
| Cheng-Mayer et al. | Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 | |
| Sharpless et al. | Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism | |
| AU600658B2 (en) | Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use | |
| US5550052A (en) | Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells | |
| Keys et al. | V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease | |
| Matsushita et al. | Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. | |
| Ikuta et al. | Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens | |
| EP0327801A1 (en) | HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions | |
| KR920008744B1 (en) | Monoclonal antibodies to hiv and related peptides | |
| Nair et al. | Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes. | |
| US5854400A (en) | Monoclonal antibodies which neutralize HIV-1 infection | |
| CZ2002402A3 (en) | Peptide that block viral infections and method for using thereof | |
| Jacobson et al. | Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. | |
| US5597896A (en) | Retrovirus human immunodeficiency virus type 2(HIV2), capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes | |
| Ranki et al. | Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins | |
| Ikeuchi et al. | Infection of nonlymphoid cells by human immunodeficiency virus type 1 or type 2 | |
| US5286852A (en) | Antibodies specific towards HIV-1 gp 48 | |
| Trujillo et al. | Molecular mimicry between the human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins | |
| US5981278A (en) | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS | |
| Altaner et al. | Envelope glycoprotein gp51 of bovine leukemia virus is differently glycosylated in cells of various species and organ origin | |
| WO1989010416A1 (en) | PROTECTIVE PEPTIDES DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS-1 gp160 |